PEOPLE - Changes at Cygnus in the US:
This article was originally published in Clinica
Cygnus in the US has announced that Gregory Lawless has resigned as president, CEO and director to pursue other interests. He is succeeded by John Hodgman, who was previously president of the group's Cygnus Diagnostics subsidiary. In addition, Andre Marion, a Cygnus director, has been elected vice-chairman. The company is developing non-invasive glucose monitoring and drug delivery systems. A distribution agreement with Becton Dickinson for the glucose monitoring system, GlucoWatch, was ended in March.
You may also be interested in...
Approved in February as an on-demand remedy, Nurtec will be filed for migraine prevention after success in Phase III. It could be the first oral preventive therapy and first dual purpose migraine drug.
A protocol amendment is not needed to pause enrollment to decrease potential exposure to COVID-19, and virtual visits can be immediately implemented to ensure safety; experts say pandemic is forcing a rethinking in how companies carry out trials and in how regulators ensure patient safety and trial integrity.
South Korea’s Qurient achieves proof of concept in a Phase II study with its first-in-class antibiotic telacebec for tuberculosis and aims to file a US NDA for the orphan drug.